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Glioblastoma multiforme (GBM) is the most 
common and deadly primary malignant brain 
tumor primarily because of its rapid growth, 
neovascularization, and invasiveness through-
out the brain (Furnari et al., 2007). Its ability to   
migrate into brain parenchyma makes it resis-
tant to multimodal therapies combining surgi-
cal resection, radiotherapy, and chemotherapy 
and results in a median survival time for pa-
tients of 12–16 mo (Stupp et al., 2005). This 
demands identification of pathways controlling 
GBM cell invasion, which complement those 
affecting its growth and angiogenesis, as an im-
portant investigative endeavor in the search for 
therapies that improve patient survival.
Attempts to understand the biology of ma-
lignant gliomas have focused on genetic and 
molecular alterations of tumor cells. The most 
common  genetic  alteration  associated  with 
GBM is amplification and/or mutation of the 
epidermal growth factor (EGF) receptor (EGFR) 
gene, a transmembrane receptor tyrosine kinase 
which has been detected in 40–60% of patients 
with GBM (Libermann et al., 1985; Wong   
et al., 1987, 1992). We previously demonstrated 
that mutant EGFR dramatically enhances the 
tumorigenicity of glioma cells in a pleiotropic 
manner by increasing proliferation and resis-
tance  to  apoptosis  (Nishikawa  et  al.,  1994; 
Nagane et al., 1996; Huang et al., 1997; Narita 
et al., 2002). However, the effect of this onco-
genic driver in the diffuse invasiveness that also 
characterizes GBM and the downstream path-
ways and effector molecules that might mediate 
this remain largely unknown.
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Although GBP1 (guanylate binding protein 1) was among the first interferon-inducible 
proteins identified, its function is still largely unknown. Epidermal growth factor receptor 
(EGFR) activation by amplification or mutation is one of the most frequent genetic lesions 
in a variety of human tumors. These include glioblastoma multiforme (GBM), which is 
characterized by independent but interrelated features of extensive invasion into normal 
brain parenchyma, rapid growth, necrosis, and angiogenesis. In this study, we show that 
EGFR activation promoted GBP1 expression in GBM cell lines through a signaling pathway 
involving Src and p38 mitogen-activated protein kinase. Moreover, we identified YY1 (Yin 
Yang 1) as the downstream transcriptional regulator regulating EGFR-driven GBP1 expres-
sion. GBP1 was required for EGFR-mediated MMP1 (matrix metalloproteinase 1) expression 
and glioma cell invasion in vitro. Although deregulation of GBP1 expression did not affect 
glioma cell proliferation, overexpression of GBP1 enhanced glioma cell invasion through 
MMP1 induction, which required its C-terminal helical domain and was independent of its 
GTPase activity. Reducing GBP1 levels by RNA interference in invasive GBM cells also 
markedly inhibited their ability to infiltrate the brain parenchyma of mice. GBP1 expression 
was high and positively correlated with EGFR expression in human GBM tumors and cell 
lines, particularly those of the neural subtype. Together, these findings establish GBP1 as a 
previously unknown link between EGFR activity and MMP1 expression and nominate it as a 
novel potential therapeutic target for inhibiting GBM invasion.
© 2011 Li et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
EGFR activity promotes GBP1 expression  
in glioblastoma cells
As a first step toward identifying the target genes of EGFR 
activity in glioma cells, genome-wide expression analyses 
were performed using the Affymetrix GeneChip Human 
Genome U133A array, which allows for the simultaneous 
study of 14,500 characterized human genes. To accom-
plish this, messenger RNA (mRNA) expression levels of 
these genes were measured in the glioblastoma cell lines, 
U87 and U178, engineered with EGFR by retrovirus trans-
duction  (termed  U87-EGFR  and  U178-EGFR,  respec-
tively), with or without 20 ng/ml EGF treatment for 3 h. 
The increased ratios (fold change) after the stimulation of 
EGF in these cells were calculated. The number of probe 
sets whose increased ratio showed more than twofold and 
more than threefold were 205 and 82 in U87-EGFR and 
334 and 140 in U178-EGFR, respectively. To further identify 
genes that could be reproducibly induced by EGF stimula-
tion  in  both  U87-EGFR  and  U178-EGFR  glioblastoma 
cell lines, the 13 probe sets (12 genes) whose expression 
were up-regulated more than threefold in all four sets of 
experiments were extracted (Table 1). Interestingly, many 
of these genes could be grouped into an IFN- response 
gene module including SOCS1 and SOCS3 (suppressor of 
cytokines signaling 1 and 3), IRF1 (IFN regulatory factor 1), 
IL-6, MCP1 and MCP2 (monocyte chemotactic protein 1 and 2), 
and GBP1. We focused on GBP1 because it was one of the 
most highly up-regulated genes in this group and its func-
tion in cancer is largely unknown.
To identify the target genes regulated by EGFR activation, 
we performed expression array analysis and found that the most 
commonly altered expression was from a gene module normally 
associated with IFN stimulation and Stat function. This included 
GBP1 (guanylate binding protein 1), initially identified as a type I 
and II IFN-induced gene, that encodes a 67-kD protein be-
longing to a large GTPase family, which includes dynamins and 
Mx proteins (Prakash et al., 2000a,b). In endothelial cells, GBP1 
can be induced by IL-1, TNF, and IFN- in vitro (Guenzi 
et al., 2001, 2003), and it is expressed in these cells in vivo 
during an inflammatory response (Lubeseder-Martellato et al., 
2002) to interfere with angiogenesis and to inhibit the expres-
sion of MMP1 (matrix metalloproteinase 1), a collagenase neces-
sary for cell migration through the extracellular matrix (Guenzi 
et al., 2003). A more recent study has demonstrated that GBP1 
overexpression is associated with paclitaxel drug resistance in 
ovarian cancer cells (Duan et al., 2006). However, how GBP1 
directs any of these actions is not clear.
In this study, we report a novel EGFR–Src–p38–YY1 
(Yin Yang 1) signaling cascade that directly induces GBP1 
expression in GBM cell lines and is distinct from the IFN-–
stimulated GBP1 expression occurring through Stat1. Fur-
thermore, we show that GBP1 is up-regulated in GBM tumor 
samples compared with the adjacent normal brain tissues and, 
consistent with our findings, is co-overexpressed with EGFR 
in GBM tumors and cell lines. Finally, in contrast to its function 
in endothelial cells, we show that GBP1 is required for EGFR 
signaling–mediated MMP1 expression and cell invasion in 
glioma cells, suggesting that GBP1 may represent a novel tar-
get for GBM therapeutics.
Table 1.  Primary genes induced by EGFR activation
Gene name Gene symbol Accession number Affymetrix probe set Fold change (EGF plus/minus)
U87-EGFR U178-EGFR
1st 2nd 1st 2nd
Chemokine (C-C motif) ligand 2/MCP-1 *CCL2 NM_002982 216598_s_at 21.1 147.0 14.9 4.9
Chemokine (C-C motif) ligand 8/MCP-2 *CCL8 NM_005623 214038_at 8.0 21.1 45.3 24.3
Guanine nucleotide binding protein (G 
protein), alpha 14
GNA14 NM_004297 220108_at 4.6 3.2 5.7 3.0
Guanylate binding protein 1 *GBP1 NM_002053 202269_x_at 13.9 16.0 8.6 7.0
Guanylate binding protein 1 *GBP1 NM_002053 202270_at 9.8 13.9 6.1 8.0
Interleukin 6 *IL6 NM_000600 205207_at 16.0 6.1 5.7 8.0
Interferon-induced protein with 
tetratricopeptide repeats 3
*IFIT3 NM_001031683 204747_at 3.7 3.7 5.3 3.5
Interferon regulatory factor 1 *IRF1 NM_002198 202531_at 9.8 5.7 13.9 14.9
Interleukin 24 IL24 NM_006850 206569_at 12.1 6.5 10.6 3.7
Nuclear receptor subfamily 4, group A, 
member 3
NR4A3 NM_006981 209959_at 52.0 12.1 8.6 16.0
Suppressor of cytokine signaling 1 *SOCS1 NM_003745 209999_x_at 4.0 5.3 6.5 8.6
Suppressor of cytokine signaling 3 *SOCS3 NM_003955 206359_at 5.7 3.2 55.7 48.5
Tenascin C TNC NM_002160 216005_at 9.8 5.3 7.5 11.3
The human HG-U133A Affymetrix arrays were performed twice in U87-EGFR and U178-EGFR cells with or without EGF stimulation. The genes whose expression was up-
regulated more than threefold in all four sets of experiments are listed. The genes that could be grouped into an IFN- response gene module are indicated by an asterisk. 
Accession numbers are from GenBank/EMBL/DDBJ.JEM Vol. 208, No. 13 
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elevated expression of GBP1 in GBM (Fig. 2 B). We then 
sought to expand our analysis of GBP1 expression in GBM 
tissues through The Cancer Genome Atlas (TCGA), a publicly 
available repository which has accumulated comparative ge-
nomic hybridization, gene expression, and DNA methyla-
tion analyses for 301 GBM samples (Cancer Genome Atlas   
Research Network, 2008). Using this database, coexpression 
of EGFR and GBP1 in GBM tumor samples was confirmed 
(R = 0.375; P < 0.001) with GBP1 expression appearing to 
correlate with GBM neural, classical, and mesenchymal sub-
types (Verhaak et al., 2010), with the neural subtype presenting 
the strongest correlation (R = 0.683; P < 0.001) and the pro-
neural subtype reliably not correlated (R = 0.112; P = 0.33; 
Fig. 2 C). Altogether, these data are consistent with the expres-
sion array results and indicate that EGFR signaling induces 
GBP1 expression in GBM.
EGFR signaling–stimulated GBP1 expression is Src–p38 
mitogen-activated protein kinase (MAPK) dependent, 
whereas IFN-–induced GBP1 expression does not require 
Src or p38 MAPK
In  response  to  EGF  stimulation,  EGFR  triggers  several 
downstream signaling cascades, including the MAPK, phos-
phatidylinositol  3-kinase  (PI3K)/AKT,  and  Stat  pathways 
(Wells, 1999). Therefore, we determined the downstream sig-
naling pathway from EGFR that leads to GBP1 up-regulation 
by using both pharmacological (using a series of specific 
chemical inhibitors) and genetic (using small interfering 
RNA [siRNA]) approaches to target known EGFR effector 
pathways. When U87-EGFR cells were pretreated with an 
EGFR inhibitor (AG1478), MEK1/2 inhibitor (U0126 or 
PD98059),  p38  inhibitor  (SB203580),  JNK1/2  inhibitor 
(SP600125), or PI3K inhibitor (LY294002) for 1 h followed 
by EGF treatment for 24 h, we ob-
served that only the EGFR or p38 in-
hibitor abrogated EGF-induced GBP1 
expression (Fig. 3 A), suggesting that 
GBP1  induction  employs  an  EGFR–
p38 signaling cascade. To eliminate 
GBP1 is up-regulated and positively correlated with EGFR 
expression in glioblastoma
Next, we validated the expression array data by RT-PCR 
and  Western  blot  analyses.  We  found  that  EGF  induced 
GBP1 expression in U87-EGFR in a time- and dose-dependent 
manner at both the mRNA and protein levels (Fig. 1, A and B). 
To determine whether the EGFR signaling–induced GBP1 
expression was directly regulated at the transcriptional level, 
U87-EGFR cells were treated with 5 µg/ml actinomycin D 
(AD; a transcription inhibitor) or 100 nM cycloheximide 
(CHX;  a  protein  synthesis  inhibitor)  for  1  h  followed  by   
EGF treatment. Fig. 1 C shows that AD prevented the EGF-
mediated  up-regulation  of  GBP1  in  U87-EGFR  cells, 
whereas no effect was observed in CHX-treated cells. These 
results suggest that EGFR signaling enhanced GBP1 expres-
sion at the level of transcription and was independent of de 
novo protein synthesis.
To determine whether the induction of GBP1 is a general 
response to EGFR activation in glioma, we also investigated 
U178-EGFR, U373-EGFR, and the GBM serial xenograft 
line, GBM26, which harbors amplification of EGFR (Sarkaria 
et al., 2007). Similar to the aforementioned results with 
U87-EGFR, it was determined that EGF also induced GBP1 
expression in each of these three additional cell lines (Fig. 1 D).
To further investigate the relationship between GBP1 and 
EGFR,  we  analyzed  their  mRNA  expression  levels  in  19 
GBM tumor tissues by quantitative RT-PCR (RT-qPCR). 
Compared with normal brain tissue, GBP1 expression was 
increased in 12 of 19 (63%) GBM samples and, importantly, 
displayed  a  positive  correlation  with  EGFR  expression   
(R = 0.624; P < 0.05; Fig. 2 A). Consistent with these qPCR 
results, mining the cancer profiling database Oncomine 
(Rhodes et al., 2004; Sun et al., 2006) showed significantly 
Figure 1.  EGFR activity promotes GBP1 
expression in GBM cells. (A and B) U87-EGFR 
cells were serum starved for 24 h and then 
stimulated with the indicated amount of EGF 
for 6 h (top) or with 20 ng/ml EGF treatment 
for the indicated time period (bottom). The 
expression of GBP1 was analyzed by semi-
quantitative RT-PCR (A) and Western blot (B).  
(C) After 24 h of serum starvation, U87-EGFR 
cells were pretreated with AD or CHX for 1 h 
followed by 20 ng/ml EGF treatment for 6 h. 
GBP1 mRNA was measured by RT-PCR.  
(D) Western blot analysis of GBP1 induction 
by EGF in three other GBM cell lines. Cells 
were serum starved and treated with 20 ng/ml 
EGF for 24 h. Data are representative of at 
least two independent experiments.2660 GBP1 drives glioblastoma invasion | Li et al.
Inhibition of c-Src activation by pretreatment of cells with 
PP2 or dasatinib, two independent Src family kinase inhibitors, 
decreased EGF-induced p38 MAPK activation (Fig. 3 C and 
not depicted). In contrast, p38 inhibition was unable to block 
Src activation, suggesting that EGFR signaling activates p38 
through Src (Fig. 3 C). Importantly, like p38 inhibition, PP2 
or dasatinib dramatically reduced the GBP1 induction by 
EGF  treatment in the three independent glioma cells lines 
(U87-EGFR, U178-EGFR, and U373-EGFR) tested (Fig. 3 D 
and not depicted).
Because IFN- is a well-known inducer of GBP1 expres-
sion in other cell types (Naschberger et al., 2004), we deter-
mined whether IFN- utilizes Src–p38 MAPK to induce 
GBP1 expression in GBM cell lines. As shown in Fig. 3 E, 
any off-target effects of the p38 inhibitors, we also used siRNA 
to knockdown p38 in U87-EGFR cells. As shown in Fig. 3 B, 
depletion of p38 by treatment with 10 nM siRNA signifi-
cantly prevented GBP1 induction by EGF. Consistent with 
this, the p38 inhibitor blocked EGF/EGFR-mediated p38 
activation, and AG1478 inhibited both EGFR and p38 phos-
phorylation (Fig. 3 C).
Because Src family kinases are associated with MAPK 
activation in response to receptor tyrosine kinase activation 
(Ishizawar and Parsons, 2004; Summy et al., 2005; Lieskovska 
et al., 2006), we determined whether Src family kinases are 
involved in p38 activation and GBP1 induction in response to 
EGFR activation. Exposure of U87-EGFR cells to EGF 
induced activation of EGFR, c-Src, and p38 (Fig. 3 C). 
Figure 2.  GBP1 is co-overexpressed with EGFR in GBM. (A) GBP1 and EGFR expression in GBM patients was measured by qPCR analysis. Normal  
denotes normal brain tissue. (right) Pearson r test. (B) Analysis of GBP1 gene expression in glioblastoma using the Oncomine database. (C) TCGA analysis of 
GBP1 and EGFR correlation in 301 GBM patient samples. The correlation is also shown in the four indicated subtypes of GBM (Verhaak et al., 2010). Classical, 
n = 82; mesenchymal, n = 88; neural, n = 55; proneural, n = 76. Data are representative of at least two independent experiments. Error bars represent SD.JEM Vol. 208, No. 13 
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Figure 3.  EGFR signaling–stimulated GBP1 expression is Src and p38 MAPK dependent, whereas IFN-–induced GBP1 expression is not.  
(A) After 24 h of serum starvation, U87-EGFR cells were treated with DMSO (), 10 µM of the EGFR tyrosine kinase inhibitor AG1478 (AG), 20 µM of the MEK 
inhibitors U0126 (U) or PD980589 (PD), 20 µM of the p38 inhibitor SB203580 (SB), 10 µM of the PI3K inhibitor LY294002 (LY), or 20 µM of the JNK inhibitor 
SP600125 (SP) for 1 h followed by 20 ng/ml EGF treatment for 24 h before Western blot analysis. (B) U87-EGFR cells were transfected with the indicated 
concentration of p38 siRNA (si-p38) or control siRNA (si-Luc) for 24 h and then serum starved for 24 h before 20 ng/ml EGF treatment for an additional 24 h 
followed by Western blot analysis. (C) U87-EGFR cells were pretreated with DMSO (), AG1478, SB203580, or PP2 (PP) for 1 h and then treated with 100 ng/ml 
EGF for 30 min before Western blot analysis. Total Src and p38 were used as loading controls. (D) U87-EGFR, U373-EGFR, and U178-EGFR cells were treated 
with DMSO (), PP2, or SB203580 for 1 h before 20 ng/ml EGF treatment for 24 h. Cells were analyzed by Western blot. (E) U87-EGFR, U373-EGFR, and 
U178-EGFR cells were treated with DMSO (), PP2, or SB203580 for 1 h before 20 ng/ml IFN- treatment for 24 h before Western blot analysis. (F) GBM26 
cells were treated with DMSO () or SB203580 for 1 h before 20 ng/ml EGF or 20 ng/ml IFN- treatment for 24 h before Western blot analysis. All data are 
representative of at least two independent experiments. (G) U87 parental or U87-EGFR cells were transfected with pGL3-237 and pRL-TK for 24 h and then 
serum starved for 24 h followed by PBS or 20 ng/ml EGF treatment for an additional 6 h. Firefly and Renilla luciferase activities were measured, and promoter 
activity is presented as the fold induction of RLU (values of firefly luciferase unit/values of Renilla) as compared with the control. This result is expressed as 
the mean of three independent experiments ± SD. *, P < 0.01. (H) U87-EGFR cells were transfected with pGL3-237 and pRL-TK for 24 h and then serum 
starved for 24 h. The starved cells were pretreated with DMSO, 10 µM PP2, or 20 µM SB203580 for 1 h and then exposed to PBS, 20 ng/ml EGF, or 20 ng/ml 
IFN- for 6 h before reporter assay. This result is expressed as the mean of three independent experiments ± SD. *, P < 0.01.2662 GBP1 drives glioblastoma invasion | Li et al.
Moreover, although p38 or Src inhibition prevented GBP1 
promoter activation by EGF stimulation (P < 0.01; 3.59- vs. 
1.41- or 1.21-fold), it failed to block its activation by IFN- 
(3.57- vs. 3.54- or 3.27-fold; Fig. 3 H). These data further 
confirm that EGFR–Src–p38 signaling up-regulates GBP1 
expression in glioma cells at the transcriptional level.
Stat1 is not required for EGFR signaling–induced  
GBP1 expression but is necessary for IFN-–mediated  
GBP1 induction
Stat1 has previously been shown to be a transcription factor that 
mediates cytokine and growth factor–induced signals down-
stream of p38 MAPK (Wells, 1999; Battle and Frank, 2002). 
Indeed, we found that both EGF and IFN- strongly acti-
vated Stat1 phosphorylation at both Ser727 and Tyr701 in 
U87-EGFR cells. However, EGF but not IFN- led to   
p38 phosphorylation. Consistently, p38 inhibition blocked 
EGF-mediated but only had a partial effect on IFN-–mediated 
Stat1 phosphorylation at both phosphorylation sites (Fig. 4 A).
Src or p38 inhibition failed to block IFN-–mediated GBP1 
induction in U87-EGFR, U178-EGFR, and U373-EGFR 
cells. Consistent with these results, p38 inhibition abrogated 
EGF but not IFN-–induced GBP1 expression in GBM26 
cells (Fig. 3 F). Collectively, these data demonstrate that in 
GBM cells, IFN- signaling–stimulated GBP1 expression is 
independent of the Src–p38 MAPK pathway, whereas the 
EGFR signaling–induced GBP1 expression requires it.
EGFR activates the GBP1 promoter through Src–p38 MAPK
The  aforementioned  results  suggest  that  EGFR  mediates 
GBP1 expression through Src–p38 MAPK. To further vali-
date this, we cloned the GBP1 proximal promoter (237 bp; 
218/19  bp)  as  described  previously  (Lew  et  al.,  1991; 
Naschberger et al., 2004) and tested whether EGFR signaling 
is able to activate it. Upon EGF treatment, EGFR signifi-
cantly  stimulated  GBP1  promoter  activity  in  U87-EGFR 
cells (3.59-fold; P < 0.01), whereas EGF had no effect on 
GBP1 promoter activation in U87 parental cells (Fig. 3 G). 
Figure 4.  Stat1 is not required for EGFR-mediated GBP1 expression. (A) U87-EGFR cells were pretreated with 20 µM SB203580 for 1 h and then exposed 
to 100 ng/ml EGF or 100 ng/ml IFN- for 30 min before Western blot analysis. Total p38 is shown as a loading control. (B and C) U87-EGFR cells were transfected 
with Stat1 siRNA (si-stat1) or the control siRNA (si-Luc) before 20 ng/ml EGF (B) or 20 ng/ml IFN- treatment (C) for 24 h, and GBP1 expression was analyzed by 
Western blot. Data are representative of two independent experiments. (D) Stat1-null U3a cells are derived from parental 2fTGH cells. U3a-S1 cells are U3a cells 
reconstituted for Stat1. The cells were treated with 0, 5, 10, 20, 50, or 100 ng/ml IFN- for 24 h before Western blot analysis. (E) U3a and U3a-s1 cells transduced 
with EGFR were treated with 20 ng/ml EGF for 24 h before Western blot analysis. Data are representative of two independent experiments.JEM Vol. 208, No. 13 
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so in parental 2fTGH and reconstituted U3a-S1 cells in which 
Stat1 was activated (Fig. 4 D). Interestingly, we observed that 
IFN- activated Stat1 in 2fTGH and U3a-f1 cells but failed to 
activate p38 phosphorylation in each of the three lines, which 
is consistent with the aforementioned results obtained in 
glioma cells (Fig. 4 D). As these three cell lines express a very 
low level of EGFR (Leaman et al., 1996), we stably expressed 
full-length human EGFR in U3a and U3a-S1 cells. In the 
Stat1-deficient U3a cells expressing EGFR, EGF was now able 
to induce GBP1 expression, whereas no further enhancement 
We next examined whether Stat1 is involved in EGFR 
signaling–mediated GBP1 induction. Although Stat1 knock-
down dramatically attenuated IFN-–induced GBP1 expres-
sion in U87-EGFR cells, it had no effect on GBP1 induction 
by EGF stimulation (Fig. 4, B and C).
To further study the role of Stat1 in GBP1 induction, we 
also used the isogenic human fibrosarcoma cell lines 2fTGH, 
U3a (2fTGH-derived Stat1-null cell), and U3a-S1 (U3a 
reconstituted for Stat1). In the Stat1-deficient U3a cells, IFN- 
was unable to induce GBP1 expression, while being able to do 
Figure 5.  YY1 is involved in regulation 
of EGFR-mediated GBP1 expression.  
(A) Schematic representation of cis intact  
(WT) and mutant (mt) YY1 binding motif in 
the GBP1 proximal promoter. (B) U87-EGFR 
cells were transfected with the GBP1 wild-
type promoter pGL3-237 and the internal 
control pRL-TK with or without 200-fold ex-
cess of YY1 wild-type or mutant decoy or the 
YY1 deactivated GBP1 promoter pGL3-237-
yy1mt and pRL-TK for 24 h and then serum 
starved for 24 h before 20 ng/ml EGF treat-
ment for 6 h. Firefly and Renilla luciferase 
activities were measured, and promoter activ-
ity was presented as the fold induction of RLU 
(values of firefly luciferase unit/values of Re-
nilla luciferase unit) as compared with the 
control. This result is expressed as the mean 
of three independent experiments ± SD.  
#, P < 0.05; *, P < 0.01. (C) U87-EGFR cells were 
transfected with YY1 or Luc-specific siRNA for 
24 h and then transfected with pGL3-237/ 
pRL-TK for 24 h. The cells were serum starved 
for an additional 24 h before 20 ng/ml EGF or 
PBS treatment for 6 h. Promoter activity was 
presented as the fold induction of RLU as 
compared with the control. The result is pre-
sented as mean ± SD of three independent 
experiments. #, P < 0.05; *, P < 0.01. (D) EMSA 
analysis. Double-strand YY1 DNA probe was 
labeled with -[32P]ATP and bound to the 
nuclear extracts of EGF- and/or SB203580-
treated U87-EGFR cells with or without pre-
incubation with a 100-fold excess of YY1 probe 
or YY1-specific antibody. (E) ChIP analysis of 
YY1 element from untreated and EGF-treated 
(100 ng/ml, 30 min) U87-EGFR cells using an 
antibody specific for YY1 or rabbit IgG control. 
Input chromatin is presented. PCR was per-
formed to amplify the proximal GBP1 pro-
moter (237 bp). This experiment was repeated 
twice, yielding identical results. (F) U87-EGFR 
cells were transfected with YY1 or control 
siRNA for 24 h and then serum starved for  
24 h before 20 ng/ml EGF stimulation for 24 h. 
GBP1 and YY1 expression were analyzed by 
Western blot. Data are representative of at least two independent experiments. (G) After 24 h of serum starvation, U87-EGFR cells were treated with 
DMSO vehicle or 20 µM of p38 inhibitor SB203580 for 1 h followed by 100 ng/ml EGF treatment for 30 min before cell fractionation and Western blot 
analysis. Data are representative of two independent experiments.2664 GBP1 drives glioblastoma invasion | Li et al.
immunoprecipitates  was  then  amplified  by  PCR  with 
primers specific for the 237-bp proximal GBP1 promoter 
(218/19 bp). As expected, no DNA fragments were detected 
when normal rabbit IgG was used (Fig. 5 E, first and second 
lanes). In contrast, DNA fragments with the expected size 
(237 bp) were detected using the anti-YY1 antibody in 
U87-EGFR cells (Fig. 5 E, third through fifth lanes). In agree-
ment with the EMSA results, EGF stimulation decreased the 
amount of GBP1 promoter DNA immunoprecipitated with 
YY1 (Fig. 5 E, fourth lane vs. fifth lane).
To further verify the role of YY1 in GBP1 induction, 
we depleted YY1 by siRNA in U87-EGFR cells. As shown 
in Fig. 5 F, Western blot analysis demonstrated that knock-
down of YY1 can increase both the basal GBP1 protein 
level and GBP1 induction by EGF in U87-EGFR cells. These 
findings suggested that YY1 functions as a negative regula-
tor of GBP1 expression and that EGFR signaling acts to   
relieve this repression.
GBP1 is required for EGFR-mediated MMP1  
expression in GBM
A previous study demonstrated that GBP1 inhibits endo-
thelial cell invasion and tube formation by down-regulating 
MMP1 expression (Guenzi et al., 2003). This led us to 
analyze the expression profiles of GBP1, MMP1, and EGFR 
in a collection of GBM tumors and cell lines. Surprisingly, it 
appears that these three proteins were overexpressed in a 
positive correlation pattern in four of eight patients and 4 of 
10 cell lines (U178, T98G, LN308, and A1207 cells; Fig. 6,   
A and B). To further validate the relationship between these 
three proteins, we compared their expression levels in U178-
EGFR cells with or without EGF stimulation using a loss of 
function strategy because these cells express relatively high 
levels of both GBP1 and MMP1. We found that EGFR acti-
vation by EGF stimulated both GBP1 and MMP1 expres-
sion. In contrast, knockdown of GBP1 by siRNA largely 
blocked EGF-mediated MMP1 induction in U178-EGFR 
cells (Fig. 6 C, left). To examine how GBP1 controls MMP1 
expression in glioma cells, we first determined whether 
EGFR-induced MMP1 expression in U178-EGFR was at 
the  transcriptional  or  translational  level.  Pretreating  these 
cells with AD or CHX completely blocked EGFR-mediated 
MMP1 mRNA expression (Fig. 6 C, right; P < 0.01), indi-
cating that MMP1 induction by EGFR activation is at the 
transcriptional level and requires de novo protein synthesis. 
As shown in Fig. 6 E, the protein levels of basal and induced 
MMP1 were increased when the si-Luc–transfected U178-
EGFR cells were posttreated with MG132, a specific protea-
some inhibitor; however, MG132 was still able to increase 
MMP1 expression in the si-GBP1–transfected cells, suggest-
ing that GBP1 had no effect on MMP1 stability. Addition-
ally, we found that reduction of GBP1 by siRNA significantly 
decreased  both  the  basal  and  the  EGFR-induced  MMP1 
mRNA expression in U178-EGFR cells (Fig. 6 D, left and 
middle; P < 0.001). To confirm this, we cloned the human 
MMP1 promoter (2,942 bp) into the pGL3-basic vector 
was detected in the U3a-S1 cells. As expected, EGFR activa-
tion by EGF stimulated p38 phosphorylation in both cells and 
Stat1 phosphorylation only in U3a-s1 cells (Fig. 4 E). Collec-
tively, these data strongly suggest that although Stat1 is essential 
for GBP1 induction by IFN-, it is dispensable for GBP1 
induction by EGFR signaling.
YY1 is an important regulator for GBP1  
induction by EGFR signaling
To identify the transcription factor that mediates GBP1 mRNA 
induction by EGFR signaling, we analyzed the GBP1 proxi-
mal promoter in silico using TFSEARCH software. In addi-
tion to a GAS (IFN-–activated sequence) element that binds 
to Stat1 (Lew et al., 1991; Naschberger et al., 2004), the proxi-
mal promoter of the GBP1 gene also contains a consensus 
YY1 motif CCATTT (CCATTTATGG; 167/158 bp; 
Fig. 5 A). To examine whether YY1 is involved in GBP1 pro-
moter activation by EGFR signaling, the YY1 binding site was 
mutated,  resulting  in  an  unexpected  increase  in  GBP1 
promoter activity compared with the intact wild-type GBP1 
promoter in response to EGF stimulation in U87-EGFR cells 
(5.6- vs. 3.5-fold; P < 0.01; Fig. 5 B). Furthermore, decoy 
experiments were performed to delineate further the involve-
ment of YY1 in EGF-induced enhancement of GBP1 gene 
transcription through the 237-bp promoter. Fig. 5 B demon-
strated that the wild-type but not the mutant YY1 decoy 
oligonucleotides further increased EGF-induced GBP1 tran-
scription (4.7- vs. 3.5-fold; P < 0.05; Fig. 5 B), implicating 
the YY1 motif as a potential repressor element. This notion 
was supported in experiments using siRNA knockdown of 
YY1 that demonstrated enhanced GBP1 promoter activity 
(P < 0.01; Fig. 5 C).
To test the binding capacity of the GBP1 promoter YY1 
motif, electrophoretic mobility shift assays (EMSAs) were per-
formed. Double-stranded oligonucleotides containing the YY1 
motif (176/142 bp) were radiolabeled and used as probes 
of nuclear extracts from U87-EGFR cells with or without 
100 ng/ml EGF treatment for 30 min as a source of YY1. Un-
labeled 100-fold excess of YY1 probe was used as a specific 
competitor. As would be predicted from the foregoing, EGF 
stimulation  decreased  YY1  DNA  binding  activity  in  U87-
EGFR cells (Fig. 5 D, third lane vs. second lane), and the 
specific band was completely blocked by unlabeled competitor 
(Fig. 5 D, fourth lane). Importantly, p38 inhibition blocked the 
DNA binding decrease induced by EGF (Fig. 5 D, sixth lane vs. 
third lane). To confirm that YY1 is indeed a component of the 
DNA–protein complex in EMSA, the effect of the anti-YY1–
specific antibody on EMSA was tested. Although the DNA–
protein complex was not super-shifted by the addition of specific 
antibody, the antibody disrupted the complex, suggesting that 
YY1 is indeed at least a component of the DNA binding com-
ponent detected in the nuclear extracts (Fig. 5 D, first lane vs. 
second lane).
To substantiate the activity of YY1 in vivo, we performed 
a chromatin immunoprecipitation (ChIP) assay by using a 
specific antibody against YY1. DNA associated with these JEM Vol. 208, No. 13 
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Figure 6.  GBP1 is required for EGFR-mediated MMP1 expression and invasion. (A) Expression profiles of EGFR, GBP1, and MMP1 in GBM patient 
samples were analyzed by Western blot (left). The band density was analyzed by ImageJ software (National Institutes of Health; right). T and N denote 
tumor and normal brain, respectively. Asterisks denote coexpression of the three proteins in the indicated samples. (B) Western blot analysis of expression 
of EGFR, GBP1, and MMP1 in GBM cell line cultures. (C, left) U178-EGFR cells were transfected with GBP1 siRNA (si-GBP1) or control siRNA (si-Luc) for 
24 h and then serum starved for 24 h before EGF stimulation for an additional 24 h. The expression of GBP1 and MMP1 was analyzed by Western blot. 
(right) RT-qPCR analysis of MMP1 expression. Serum-starved U178-EGFR cells were pretreated with AD or CHX for 1 h followed by 20 ng/ml EGF treat-
ment for 6 h. *, P < 0.01. (D) RT-qPCR analysis of GBP1 (left) and MMP1 (middle) mRNA expression was performed in U87-EGFR cells transfected with  
si-Luc or si-GBP1 in the presence or absence of 20 ng/ml EGF for 6 h. Human MMP1 promoter activity was determined by cotransfecting pGL3-MMP1 
(2,942 bp) and pRL-TK (internal control) with siRNA targeting GBP1 (si-GBP1) or luciferase control (si-Luc) into U87-EGFR cells with or without 20 ng/ml 
EGF treatment for 6 h. (right) Firefly and Renilla luciferase activities were measured, and promoter activity is presented as the fold induction of RLU as 
compared with the control. This result is expressed as the mean of three independent experiments ± SD. *, P < 0.01; **, P < 0.001. (E) U178-EGFR/si-Luc 
and U178-EGFR/si-GBP1 cells were treated with or without 20 ng/ml EGF for 24 h followed by 10 µM MG132 treatment for 6 h before Western blot  
analysis. (F) U178-EGFR/si-Luc and U178-EGFR/si-GBP1 cells were treated with or without 20 ng/ml EGF for 24 h followed by analysis of cell invasion 
using BioCoat Matrigel invasion chambers. *, P < 0.05. Data are representative of three independent experiments. Error bars represent SD. Bar, 100 µm.2666 GBP1 drives glioblastoma invasion | Li et al.
cell line, SNB19 (Fig. 8 A). Because SNB19 cells express a 
relatively low level of EGFR, EGF is unable to induce GBP1 
expression (which needs a high level of EGFR in glioma 
cells, as shown in Fig. 3 G). In contrast, EGF is able to induce 
MMP1 expression that is mainly localized in the conditioned 
medium (Fig. 8 A). Importantly, knockdown of GBP1 sig-
nificantly reduced both the basal and the EGF-induced MMP1 
expression at both mRNA and protein level (Fig. 8, A and B), 
similar to our results obtained with U87 and U178 EGFR-
overexpressing cell lines. Consistently, we showed that GBP1 
reduction by siRNA dramatically inhibited the human MMP1 
basal promoter activity and EGF-stimulated promoter activa-
tion (Fig. 8 B, right).
We then stereotactically implanted SNB19-shGFP and 
SNB19-shGBP1 cells into the brains of immunocompromised 
mice. Microscopic analysis of brain sections showed that the 
mice implanted with control SNB19-shGFP cells developed 
diffuse tumors, whereas mice implanted with SNB19-shGBP1 
cells developed circumscribed tumors (Fig. 8 C). The control 
SNB19-shGFP tumor-bearing mice revealed focal and inva-
sive lesions, often in periventricular regions of the brain, as 
expected for this highly invasive GBM cell line. In contrast, 
SNB19-shGBP1 cells formed tumors with smooth tumor–
parenchyma interfaces with an associated decrease in glioma 
cell infiltration and associated infiltrative tumor masses (Fig. 8, 
C and E). In addition, consistent with in vitro results show-
ing that GBP1 mediates MMP1 expression in glioma cells 
(Fig. 8 A), we observed a dramatic decrease in GBP1 and MMP1 
expression, which are mainly localized in the cytoplasm of 
the cancer cells, in SNB19-shGBP1 tumor tissues (Fig. 8 C). 
Interestingly, large perivascular infiltrations were observed in 
the SNB19-shGFP but not the SNB19-shGBP1 tumor-bearing 
mice (Fig. 8 D). The functional specificity of GBP1 action in 
tumor cell invasion is underscored by the minimal effects it 
had on cellular proliferation, apoptosis, and angiogenesis in vivo 
(Fig. 9 A), consistent with results showing that deregulation 
of GBP1 had no effect on glioma cell proliferation in vitro 
(Fig. 9 B). These results strongly support the conclusion that 
GBP1 is specifically involved in glioblastoma invasion both 
in vitro and in vivo.
DISCUSSION
A previous study has shown that GBP1 is the most abundant 
protein induced by IFNs, with IFN- being the most effective 
(Cheng et al., 1983). In this study, we show for the first time 
that EGFR can also induce GBP1 expression in GBM cell 
lines through an Src–p38 MAPK–YY1 signaling pathway. 
Significantly,  we  found  that  GBP1  is  coexpressed  with 
EGFR in GBMs and that GBP1 could increase GBM cell inva-
sion by modulating MMP1 expression through its C-terminal 
helical domain in a GTPase-independent manner. This ability 
to enhance GBM cell invasion establishes GBP1 as a novel 
target for anti-GBM invasion therapy. In contrast to our 
finding of Src–p38 MAPK induction of GBP1 in glioma 
cells,  this  pathway  is  not  required  for  IFN-–induced 
(Armstrong  et  al.,  2009).  The  reporter  assay  showed  that 
knockdown  of  GBP1  dramatically  reduced  the  basal  and 
EGF-induced MMP1 promoter activation (Fig. 6 D, right;   
P < 0.01). Similar data were obtained in another glioma cell 
line, U87-EGFR, in which MMP1 was mainly secreted in 
the culture medium (not depicted). Collectively, these data 
demonstrate that GBP1 contributes to the basal and EGFR-
mediated MMP1 transcription in glioma cells.
GBP1 enhances glioma cell invasion through MMP1 
induction in vitro and in vivo
Given the important role that MMP1 plays in glioma pro-
gression and invasion and its correlation with GBP1 expres-
sion (Stojic et al., 2008), we examined the potential role of 
GBP1 in glioma cell invasion. We first examined whether 
GBP1  is  involved  in  EGF-mediated  glioma  cell  invasion. 
Knockdown of GBP1 significantly inhibited EGF-mediated 
U178-EGFR and U87-EGFR cell invasion through extra-
cellular  matrix  (Fig.  6  F  and  not  depicted).  Conversely, 
overexpression  of  GBP1  in  A1207  cells  dramatically  in-
creased MMP1 expression at the transcriptional level (Fig. 7,   
A and B) and enhanced cell invasiveness (Fig. 7 D), whereas 
in contrast, siRNA knockdown of MMP1 abolished GBP1-
mediated cell invasion (Fig. 7, C and D). Together, these 
data suggest that GBP1 is involved in EGFR-mediated gli-
oma cell invasion through modulation of MMP1 expression.
GBP1 is a member of a large GTPase family (Prakash 
et al., 2000a,b; Guenzi et al., 2001). To assess whether the 
GTPase activity of GBP1 is involved in MMP1 induction, we 
created two different dominant-negative mutants of GBP1, 
D184N, and R48P, which exhibit no detectable GTP bind-
ing or hydrolysis (Guenzi et al., 2003; Praefcke et al., 2004). 
As shown in Fig. 7 (E and F), both the wild-type and GTPase 
mutant alleles of GBP1 increased MMP1 protein expression 
and protease activity. Similarly, we observed that overexpres-
sion of GBP1 and these two mutant alleles also increased 
MMP1 expression in U178 cell lines (not depicted). Next, 
we characterized the role of the individual domains of GBP1 
in MMP1 induction. We cloned the truncated N-terminal 
globular domain (Glo; 1–290 aa), which harbors GTPase 
activity, and the C-terminal helical domain (Hel; 288–592 aa)   
of GBP1 into the pBABE-puro vector to allow for retro-
viral expression (Fig. 7 G). We found that the C-terminal 
helical domain but not the globular domain could induce 
MMP1 induction (Fig. 7 H). Furthermore, we observed that 
the helical domain alone could induce cell invasiveness   
(Fig. 7 I), which further suggests that the GTPase activity   
of GBP1 is not required for MMP1 expression and glioma 
cell invasion.
The invasive behavior of glioma cells in vitro may not 
completely reflect their infiltrative phenotype in the brain 
because of the differences in extracellular components (Bellail 
et al., 2004). To determine whether the in vitro effects we 
observed extended to the in vivo situation, we targeted GBP1 
expression (and GFP as a control) by lentiviral short hairpin 
RNA (shRNA) transduction in the invasive glioblastoma JEM Vol. 208, No. 13 
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Figure 7.  The helical domain of GBP1 is essential for MMP1 induction and GBM cell invasion. (A) The expression of the protein was analyzed by Western 
blot in A1207-LacZ and A1207-GBP1 cells. (B) RT-qPCR analysis of MMP1 mRNA expression was performed in A1207-LacZ and A1207-GBP1 cells (left). Reporter 
assays were performed to analyze the effect of GBP1 expression on MMP1 promoter activation in the A1207 cells (right). The cells were transfected with pGL3-MMP1 
(2,942 bp) and pRL-TK for 48 h. Firefly and Renilla luciferase activities were measured, and promoter activity is presented as the fold induction of RLU as compared 
with the control. This result is expressed as the mean of three independent experiments ± SD. *, P < 0.01. (C) The expression of the protein was analyzed by Western 
blot in siRNA-Luc (control)– and siRNA-MMP1–transfected A1207-GBP1 cells. (D) Cell invasion was analyzed by BioCoat Matrigel invasion chambers. A1207-lacZ, 
A1207-GBP1, A1207-GBP1/siRNA-Luc, or A1207-GBP1/siRNA-MMP1 cells were plated at a density of 2.0 × 104 per insert. Medium with 10% FBS was in the lower 
chamber as a chemoattractant. After 22 h, invasive cells on the lower surface were counted after fixing and staining. Shown are representative data of at least two 
independent experiments. Bar, 100 µm. (E) The expression of MMP1, GBP1, and dominant-negative mutants (D184N and R48P) of GBP1 in A1207 cells was analyzed 
by Western blot. (F) Zymography analysis of the MMP1 activity in A1207 cells expressing GBP1 or its mutants D184N and R48P. (G) Schematic representation of the 
retroviral expression vector pBABE-puro encoding individual domains of GBP1: N-terminal globular domain (Glo-GBP1; Glo) and C-terminal helical domain  
(Hel-GBP1; Hel). The numbers refer to the positions of the amino acids in GBP1. (H) Effect of Flag-tagged GBP1 and truncated Glo and Hel on the expression of MMP1 in 
A1207 cells were analyzed by Western blot. (I) Quantitative results for the invasive ability of A1207 cells expressing GBP1 or two different truncated domains Glo and 
Hel as assessed by BioCoat Matrigel invasion chambers as described in D. Data are representative of three independent experiments. Error bars represent SD.
GBP1 expression, as IFN- was unable to activate p38, a 
result which is consistent with a previous finding that cell 
stress,  such  as  bacterial  LPS,  UV  irradiation,  and TNF, 
causes  activation  of  p38  MAPK–dependent  target  gene 
transcription, whereas p38 inhibition does not affect IFN-–
mediated transcription (Kovarik et al., 1999).2668 GBP1 drives glioblastoma invasion | Li et al.
at  both  sites,  only  EGF  activated  p38  phosphorylation. 
Consistent with this, p38 inhibition blocked EGF- but not 
IFN-–stimulated Stat1 phosphorylation and GBP1 pro-
moter activity and expression as well. This is in agreement 
with earlier findings that p38 activity is dispensable for   
the IFN-–induced Stat1 phosphorylation (Kovarik et al., 
1999;  Ramsauer  et  al.,  2002).  In  addition,  it  has  been   
reported  that  LPS-,  UV  irradiation–,  or 
TNF stress–stimulated Stat1 Ser727 phos-
phorylation occurred through a signaling 
pathway sensitive to the p38 MAPK inhib-
itor SB203580, whereas IFN-–mediated 
Stat1 Ser727 phosphorylation was not 
inhibited  by  this  inhibitor  (Kovarik   
et al., 1999). Therefore, we speculate that 
EGFR  may  use  a  signaling  pathway 
similar to that used under stress to induce 
GBP1 expression.
Both EGF and IFN- are able to cause phosphorylation 
of Stat1 at both Tyr701 and Ser727 for its full activation. 
Phosphorylation of Stat1 at Tyr701 induces Stat1 dimeriza-
tion, nuclear translocation, and DNA binding (Ihle et al., 
1994), whereas Stat1 Ser727 phosphorylation strongly in-
creases its transactivation activity (Wen et al., 1995). Al-
though EGF and IFN- caused phosphorylation of Stat1 
Figure 8.  Targeting GBP1 inhibits glioblas-
toma invasion in vivo. (A) Western blot analysis 
of MMP1 and GBP1 in cell lysates (CL) and of 
MMP1 in conditioned medium (CM) of SNB19-
shGFP and -shGBP1 cells with or without 20 ng/ml 
EGF stimulation for 24 h. (B) RT-qPCR analysis  
of GBP1 (left) and MMP1 (middle) mRNA expres-
sion in SNB19-shGFP and SNB19–shGBP1 cells 
with or without PBS or 20 ng/ml EGF stimulation 
for 6 h. (right) The human MMP1 promoter activ-
ity was determined by transfecting with pGL3-
MMP1 (2,942 bp) and pRL-TK (internal control) in 
the shRNA-transfected SNB19 cells with or with-
out PBS or 20 ng/ml EGF treatment for 6 h. Firefly 
and Renilla luciferase activities were measured, 
and promoter activity is presented as the fold 
induction of RLU as compared with the control. 
This result is expressed as the mean of three inde-
pendent experiments ± SD. *, P < 0.05; #, P < 0.01. 
(C) H&E, GBP1, and MMP1 staining of brain sec-
tions on day 20 after intracranial inoculation of 
SNB19-shGFP (left) or SNB19-shGBP1 (right;  
1 × 106 cells/mouse). Shown are representative 
brain slices from tumor-bearing mice. Tumor 
margins are delineated using a dotted line. Arrow-
heads denote invasive extensions from tumor 
mass (T). Arrows indicate invasive tumor cells and 
disseminated tumor clusters away from the  
tumor mass. The animal experiments were per-
formed two independent times with 10 mice per 
group with similar results. (D) Representative 
image showing perivascular infiltrations in 
SNB19-shGFP (left) but not SNB19-shGBP1 
(right) tumor-bearing mice. Bars, 50 µm.  
(E) Quantification of the infiltrating tumor masses 
observed in SNB19-shGFP and SNB19-shGBP1 
tumor-bearing mice on day 20 (n = 10; *, P < 0.05). 
Data are representative of two independent  
experiments. Error bars represent SD.JEM Vol. 208, No. 13 
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YY1 and PRC2, leading to the formation of repressive 
chromatin on the Pax7 promoter (Palacios et al., 2010).
Given that EGFR kinase activity can up-regulate GBP1 
expression in vitro, we compared the expression profile of 
EGFR and GBP1 in a panel of GBM tumor samples and cell 
lines. Together with TCGA analysis, the data suggest that 
both EGFR and GBP1 are highly expressed and show the 
strongest correlation with the neural subclass of GBM, which 
is in agreement with the idea that EGFR amplification is one 
of the signatures for this subclass (Verhaak et al., 2010). Our 
results are also consistent with a recent study showing that 
GBP1 is overexpressed in all gliomas with EGFR amplifica-
tion (Ducray et al., 2008). Interestingly, we observed that 
EGFR, GBP1, and MMP1 expression appears to be posi-
tively  correlated  with  each  other  in  GBM  patients  and   
cell lines. More importantly, GBP1 is required for EGFR-
mediated MMP1 transcription, and GBP1 mediates MMP1 
expression  at  the  transcriptional  level  in  glioma 
cells. Thus, this may explain why these proteins 
display such concordance of expression in GBM.
Overexpression of EGFR has been shown   
to  promote  glioma  cell  motility  and  invasion 
(Pedersen et al., 2004; Cai et al., 2005), and the 
Src  and  p38  pathway  have  been  implicated  in 
glioma invasion previously (Park et al., 2002; 
Angers-Loustau et al., 2004; Demuth et al., 2007; 
Lu et al., 2009). However, the basis for initiation 
and maintenance of the aberrant motility is still 
not known. Numerous studies suggest that EGFR 
activation causes MMP1 expression, which is 
associated with invasion and metastasis of cancer 
cells (Nutt and Lunec, 1996; Nutt et al., 1998; 
Itoh et al., 2006; Cury et al., 2007). As GBP1 can 
also be induced by inflammatory cytokines and 
down-regulates MMP1 expression in endothelial 
cells (Guenzi et al., 2001, 2003), we investigated 
the  functional  relationship  between  these  three 
proteins in GBM cell lines. We found that GBP1 
is induced by the EGFR–Src–p38 cascade and is 
sufficient for EGFR-mediated MMP1 expression 
and  cell  invasion.  Moreover,  overexpression  of 
GBP1  alone  enhanced  GBM  cell  invasion  by 
up-regulating MMP1. Our finding that in GBM 
cells GBP1 acts as a positive regulator of MMP1 
We  identified  YY1,  a  ubiquitous  and  dual-functional 
GLI-Krüppel zinc finger transcription factor, as a potential 
transcriptional repressor for GBP1 induction in GBM cells. 
Depending  on  cell  type–specific  factors  and  its  relative 
concentration, the promoter sequences surrounding the YY1 
binding sites, and its cellular environment, YY1 can function 
as a transcriptional activator or repressor (Yao et al., 2001). 
The present study showed that EGFR signaling attenuated 
YY1 binding to the GBP1 promoter mediated by p38 MAPK. 
We also showed by cell fractionation that EGF stimulation 
has no effect on YY1 translocation with or without p38 
inhibition (Fig. 5 G). It is possible that EGFR–Src–p38 
signaling may affect YY1 activation or its interaction with 
other transcriptional factors, which in turn affects the tran-
scriptional activity of the GBP1 promoter. In agreement with 
this possibility, a recent study has demonstrated that TNF-
activated  p38  kinase  promotes  the  interaction  between 
Figure 9.  Effect of GBP1 on glioblastoma cell growth 
in vivo and in vitro. (A) Shown is the representative Ki67, 
Tunel, and CD31 staining image of the tumor mass of 
SNB19-shGFP (left) and SNB19-shGBP1 (right) on day 20 
after intracranial inoculation. Data are representative of two 
independent experiments. Bars, 50 µm. (B and C) WST-1 
assay was performed to examine the effect of overexpression 
of GBP1 on A1207 cell proliferation (B) and the effect of 
knockdown of GBP1 by shRNA on U178 cell proliferation (C). 
Data are representative of three independent experiments. 
Error bars represent SD.2670 GBP1 drives glioblastoma invasion | Li et al.
of surgery after written informed consent. Frozen tumor samples were 
ground in liquid nitrogen and lysed in RIPA buffer for Western blot analysis. 
Total RNA was isolated from frozen tumor samples using the RNeasy 
kit (QIAGEN) according to the manufacturer’s instructions.
Microarray probe preparation and Affymetrix GeneChip hybridiza-
tion. U87 and U178 cells engineered to express EGFR were serum starved for 
24 h and stimulated with or without 20 ng/ml of recombinant EGF for 3 h 
before sample collection. The experiment was replicated twice for each U87 and 
U178 cells for microarray analyses. Transcriptional profiling was performed on 
human HG-U133A arrays (Affymetrix), which contain 22,283 probe sets 
representing 14,500 human genes and expressed sequence tags, according to 
the manufacturer’s protocol. Biotin-labeled cRNA was synthesized from 10-µg 
aliquots of total RNA from each sample, and hybridization, washing, and detec-
tion of signals were performed. Microarray Analysis Suite 5.0 software (Affyme-
trix) was used to calculate and compare the gene expression levels. Microarray 
data were deposited in GEO DataSets under accession no. GSE33442.
Western blots and antibodies. Cells were lysed in RIPA buffer (150 mM 
NaCl/1.0% Triton X-100/0.5% Na deoxycholate/0.1% SDS/50 mM Tris, 
pH 8.0/complete protease inhibitor; Roche). The conditioned media was 
collected and centrifuged at 1,000 g to remove cell debris. The supernatant 
was concentrated using Amicon centrifugal filters (Millipore). Primary anti-
bodies  used  were  anti-YY1  (c20),  anti-p38  (Santa  Cruz  Biotechnology, 
Inc.), anti-EGFR (c13; BD), anti–p-EGFR (Y1068), anti-Stat1, anti–p-Stat1 
(Y701), anti-Hsp27, anti–p-Hsp27 (S82), anti–-actin (Cell Signaling Technol-
ogy),  anti–p-Stat1  (S727;  Biosource  International,  Inc.),  anti-GBP1 
(MBL International), and anti-MMP1 (R&D Systems).
RT-PCR and real-time qPCR. Total RNA was harvested by TRIZOL 
reagent (Invitrogen) and reverse transcribed (SuperScript II First Strand kit; 
Invitrogen). Semiquantitative RT-PCR conditions were as follows: 30 s   
at 94°C, 30 s at 55°C, and 1 min at 72°C for 26 cycles. The primer pairs 
for GBP1 were sense, 5-TGGAACGTGTGAAAGCTGAG-3; and anti-
sense, 5-TGACAGGAAGGCTCTGGTCT-3; for EGFR were sense,   
5-GAGAGGAGAACTGCCAGAA-3; and antisense, 5-GTAGCATTT-
ATGGAGAGTG-3; and for GAPDH were sense, 5-TGCCTCCTGCA-
CCACCAACT-3; and antisense, 5-CCCGTTCAGCTCAGGGATGA-3.
qPCR was performed with 2 µl of diluted cDNA on an iCycler IQ   
using IQ Syber Green (Bio-Rad Laboratories) according to the manufacturer’s 
instructions. All reactions were performed in duplicate and repeated at least 
three times. Relative quantification was performed for each sample and nor-
malized with GAPDH or -actin expression for comparison. Primers used 
for real-time PCR were EGFR (104 bp): sense, 5-TTTGCCAAGGCAC-
GAGTAACA-3; and antisense, 5-ATTCCCAAGGACCACCTCACA-
3; GBP1 (197 bp): sense, 5-AACGACAGGGTCCAGTTGCTGAAAG-3; 
and  antisense,  5-TAGGGGTGACAGGAAGGCTCTGG-3;  GAPDH 
(131 bp): sense, 5-CCACATGGCCTCCAAGGAGTAAGAC-3; and anti-
sense, 5-AGGAGGGGAGATTCAGTGTGGTGGG-3; -actin (141 bp): 
sense, 5-AGAAGGAGATCACTGCCCTGGCACC-3; and antisense, 
5-CCTGCTTGCTGATCCACATCTGCTG-3; and MMP1 (234 bp): 
sense,  5-ATGCTGAAACCCTGAAGGTG-3;  and  antisense,  5-CTGC-
TTGACCCTCAGAGACC-3.
Nuclear protein extraction. Cells were resuspended in buffer A (10 mM 
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM 
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 
1 µg/ml pepstatin A), lysed with 0.625% Nonidet P-40, and centrifuged at 
3,000 rpm for 5 min at 4°C. The supernatant was collected and used as the 
cytoplasmic extracts. The nuclei pellet was washed twice with buffer A and 
resuspended in 40 µl buffer B (20 mM Hepes, pH 7.9, containing 1.5 mM 
MgCl2, 450 mM NaCl, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM 
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and   
1 µg/ml pepstatin A) and agitated for 60 min at 4°C, and the nuclear debris   
was spun down at 20,000 g for 15 min. The supernatant (nuclear extract) was 
collected and stored at 80°C until ready for analysis.
expression instead of MMP2 and MMP14 while in endothe-
lial cells it acts in the opposite fashion (Guenzi et al., 2003; 
unpublished data) is particularly intriguing. It is possible that 
this switch in function is caused by additional molecular 
aberrations specific to the tumor cells. Alternatively, this 
difference may be tissue specific and caused by the differen-
tial expression of transcription factor networks in the brain 
versus the endothelium or by differences between the nor-
mal and transformed state of the cell. We are actively in-
vestigating these possibilities.
In summary, this study demonstrates that GBP1 expres-
sion in GBM cells is up-regulated by EGFR through a unique 
p38  MAPK–dependent  relief  of  transcriptional  repression 
mediated by YY1. In addition, GBP1 is required for EGFR-
induced MMP1 expression and glioma cell invasion. Our 
identification of a novel signaling pathway controlling glioma 
invasion may have significant clinical implications because it 
uncovers several key molecules, the targeting of which may 
serve to inhibit glioma invasion, one of the key obstacles to 
achieving effective management of this disease.
MATERIALS AND METHODS
Reagents and plasmids. Pan Src inhibitor PP2, dasatinib, p38 inhibitor 
SB203580,  Mek1/2  inhibitors  U0126  and  PD98059,  JNK1/2  inhibitor 
SP600125,  PI3K  inhibitor  LY294002,  EGFR  inhibitor  AG1478,  and 
MG132 were obtained from EMD. N-terminal Flag-tagged GBP1 and its 
mutants GBP1 D184N, R48P, Glo, and Hel were cloned as described 
previously (Guenzi et al., 2001) and inserted into retrovirus vector pBABE-
puro. pLKO.1-shRNA-GFP and -GBP1 constructs were obtained through 
the RNAi Consortium shRNA Library (Broad Institute of Massachusetts 
Institute of Technology and Harvard). The human GBP1 promoter 237 bp 
(218/19 bp) was cloned by PCR using specific primers sense (5-AGCTTCT-
GGTTGAGAAATCTTTAAACC-3) and antisense (5-TGGCTTCTAG-
CACTTCTGTGTCTCTC-3)  and  inserted  into  the  firefly  luciferase 
vector, pGL3 basic (Promega). To generate a construct with mutation of the 
YY1-binding  elements,  the  QuikChange  site-directed  mutagenesis  kit 
(Agilent Technologies) was used to change the potential YY1 binding motif 
from CCATTT to TTATTT.
Cell culture and gene transfection. All GBM cell lines were cultured in 
DME with 10% FBS. SNB19 cells were a gift from W. Debinski (Wake 
Forest University, Winston-Salem, NC). GBM xenografts procedures have 
previously been described (Sarkaria et al., 2007). GBM26 xenograft cells 
were cultured as nonadherent neurospheres in neural stem cell medium to 
maintain EGFR expression. 2fTGH, U3a, and U3a-s1 cells were provide by 
G. Stark (Cleveland Clinic Foundation Research Institute, Cleveland, OH) 
and cultured in DME/10% FBS medium.
Virus  production  and  infection.  To  produce  retrovirus,  293T  cells   
were transfected with pBABE-puro–LacZ, GBP1, or its mutants together 
with pCL10A1 using Lipofectamine 2000 (Invitrogen). To produce len-
tiviruses,  293FT  cells  were  cotransfected  by  pLKO.1-shRNA-GFP   
(5-CAAGCTGACCCTGAAGTTCAT-3) or -GBP1 (5-CGGAAATTC-
TTCCCAAAGAAA-3) with pCMVDR8.91 and pMD.G-VSV-G using   
Lipofectamine 2000. Viral supernatants were harvested and filtered (0.45 µm) 
at 48 and 72 h after transfection. Glioma cells were infected overnight in 
the presence of 8 µg/ml polybrene and then selected for 5 d in growth 
medium containing 1 µg/ml puromycin. The stable clones were verified by 
Western blot.
Clinical  samples.  GBM  samples,  provided  by  R.  Nishikawa  (Saitama 
Medical University, Hidaka-shi, Saitama, Japan), were obtained at the time JEM Vol. 208, No. 13 
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(Invitrogen). In brief, after electrophoresis, the gel was incubated in renaturing 
buffer with gentle agitation. The gel was subsequently equilibrated and devel-
oped in developing buffer and stained in SimplyBlue SafeStain (Invitrogen).
Intracranial xenograft model and histological analysis. 1 × 106 of 
SNB19-shGFP or -shGBP1 cells in 5 µl PBS were injected intracranially 
into 4–5-wk-old athymic nude mice using a guide screw system as described 
by Lal et al. (2000). After 14–20 d, mice were euthanized, and their brains 
were removed and embedded in paraffin. All animal experiments conformed 
to ethical principles and guidelines approved by the University of California, 
San Diego Institutional Animal Care and Use Committee. Brain tissues were 
sectioned and stained with CD31 (Abcam), Ki67 (Abcam), Tunel (Abcam), 
GBP1 1B1 (MBL International), MMP1 Ab-6 (Thermo Fisher Scientific), 
and hematoxylin and eosin (H&E) staining (University of California, San 
Diego Histology core).
Statistical analysis. Correlation analysis between GBP1 and EGFR ex-
pression in human glioma samples was analyzed for significance using Prism 
5.0 software (GraphPad Software) with Pearson r test, where P < 0.05 was 
considered statistically significant. For other experiments, results are ex-
pressed as the mean ± SD. Statistical analyses were performed by Student’s   
t test. P < 0.05 was considered statistically significant.
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